Opna Immuno-Oncology Ltd
Therapies to disrupt immuno-suppressive barriers in cancer
Opna Immuno-Oncology SA (Opna-IO) is a biotechnology company recently spun-off from the Swiss Institute of Experimental Cancer Research within the École Polytechnique Fédérale de Lausanne (EPFL). The Company is developing first in-class therapies to disrupt immuno-suppressive barriers in cancer cells so as to enhance the capability of the body's immune system to attack human tumors.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
16.09.2024
Positive clinical progress in the biotech scene (startupticker.ch)
22.11.2022
Opna Bio Launches with $38 Million Series A Financing (startupticker.ch)
No milestones
No Jobs
No videos and documents
Opna Immuno-Oncology Ltd
Therapies to disrupt immuno-suppressive barriers in cancer
Headquarter:
St-Sulpice
Foundation Date:
September 2020
Technology:
- Biotech
Sectors:
- Biotech
- Cancer